Good news for Dutch life sciences community: EMA moves to Amsterdam

The move of EMA is good news for all patients in Europe. EMA can continue to coordinate the evaluation and monitoring of new, innovative medicines without delay and will still be able to respond quickly and effectively in the event of problems with a given medicine. EMA Executive Director Guido Rasi expressed relief about the decision: “Amsterdam ticks many of our boxes. It offers excellent connectivity and a building that can be shaped according to our needs.” This is also a nice compliment to the Dutch life sciences and health community.

As a regulatory body, the EMA is responsible for scientific evaluation, supervision and safety monitoring of medicines in the EU. Working together will benefit the regulatory system, by speeding up innovation, improving resource allocation and protecting the interests of everyone involved. One example is the enabling platform ADAPT SMART, for the coordination of Medicines Adaptive Pathways to Patients (MAPPs) activities. This project, led by the European Medicines Agency, is coordinated by Lygature as independent entity. Through our portfolio of regulatory innovation initiatives, including ADAPT SMART, but also Escher and the NBCD working group, Lygature will continue to contribute to the advancement of this field to ensure safe and medical solutions for patients.